3 H]pentamidine into wild-type and drug-resistant strains of Leishmania mexicana was compared. Uptake was carrier mediated. Pentamidine-resistant parasites showed cross-resistance to other toxic diamidine derivatives. A substantial decrease in accumulation of the drug accompanied the resistance phenotype, although the apparent affinity for pentamidine by its carrier was not altered when initial uptake velocity was measured. The apparent V max , however, was reduced. An efflux of pentamidine could be measured in both wild-type and resistant cells. Only a relatively small proportion of the total accumulated pentamidine was available for efflux in wild-type cells, while in resistant cells the majority of loaded pentamidine was available for release. Pharmacological reagents which diminish the mitochondrial membrane potential reduced pentamidine uptake in wild-type parasites, and the mitochondrial membrane potential was shown to be reduced in resistant cells. A fluorescent analogue of pentamidine, 4,6-diamidino-2-phenylindole, accumulated in the kinetoplast of wild-type but not resistant parasites. These data together indicate that diamidine drugs accumulate in the Leishmania mitochondrion and that the development of the resistance phenotype is accompanied by lack of mitochondrial accumulation of the drug and its exclusion from the parasites.
Leishmania mexicana, a flagellated protozoan parasite, is the causative agent of localized and diffuse cutaneous leishmaniasis. Sandflies transmit promastigote forms of the parasite to the mammalian host, where they invade macrophages and transform into amastigotes. Pentavalent antimonial drugs are the standard first-line treatment for leishmaniasis (1, 18) , although resistance is a growing problem (42, 44, 56, 57) . The aromatic diamidine pentamidine, initially developed for use against Trypanosoma brucei, is considered an alternative to pentavalent antimony in treatment of leishmaniasis (2, 14, 52, 55) .
Previous work on pentamidine uptake has indicated that the drug is accumulated by saturable, transport-mediated processes in African trypanosomes (23, (27) (28) (29) and in Leishmania spp. (7, 17) . The P2 adenosine transporter of Trypanosoma brucei (23) appears to play some part in the transport of this drug, although the situation is complex (24, 47) , with at least two additional transporters also capable of carrying the drug (29) . In Leishmania donovani, pentamidine was found to be a competitive inhibitor of arginine transport (40, 41) and a noncompetitive inhibitor of putrescine and spermidine transport in Leishmania infantum (51) , L. donovani, and L. mexicana (12) . With the exception of the P2 nucleoside transporter in T. brucei, the physiological roles of the carrier proteins which accumulate pentamidine have yet to be identified.
Resistance to pentamidine has been described for trypanosomes (15, 16) , L. donovani (42, 56, 59) , and other Leishmania species (8-11, 32, 53, 54) . The mechanism(s) of resistance in trypanosomatids is poorly understood. However, yeasts are also susceptible to pentamidine (45) , and a gene called PNT1, when overexpressed, confers resistance to the drug in Saccharomyces cerevisiae (46) . The protein encoded by this gene localizes to the inner membrane of the mitochondrion and appears to play a role in secretion of proteins from the mitochondrion (36) . Disruption of mitochondrial function has been proposed as a likely toxic effect of pentamidine in S. cerevisiae (36, 47) . The mitochondrion has also been implicated in the action of pentamidine against trypanosomatids. Electron microscopy revealed that treatment of Leishmania spp. with pentamidine leads to disintegration of the kinetoplast and mitochondrion (26, 37) , and a collapse in mitochondrial membrane potential (58) is one of the first manifestations of treatment of these parasites with the drug.
Mechanisms of drug resistance have been extensively studied in trypanosomatid parasites (19) . In African trypanosomes, uptake of diamidines, including pentamidine (22) and berenil, appears to involve the P2 nucleoside transporter (23) , and loss of this transporter can mediate resistance to diamidines (5, 6, 22) . However, P2-deficient T. brucei strains remain sensitive to pentamidine, probably because this diamidine continues to accumulate through alternative transporters (29) .
The aim of the present work was to study how the accumulation of pentamidine in L. mexicana and its efflux relate to pentamidine resistance in these parasites. (35) . L. mexicana (MNYC/BZ/62/ M379) amastigotes were grown at pH 5.5 in Schneider's Drosophila medium (Gibco) supplemented with 20% (vol/vol) heat-inactivated fetal calf serum and gentamicin sulfate at 25 g/ml and 32°C (13) . L. mexicana promastigotes resistant to pentamidine were obtained in vitro from sensitive L. mexicana cells by stepwise exposure to the drug with final concentrations of 2.5 M, 5 M, 10 M, and 30 M until they had no effect on parasite growth, as previously described for other Leishmania species (9) . L. mexicana amastigotes resistant to pentamidine were obtained axenically by transformation of promastigotes resistant to 30 M pentamidine at 32°C without drug pressure (13) . Once transformed, parasites were cultivated with 30 M pentamidine. The stability of pentamidine resistance in vitro was determined as described previously (9) .
MATERIALS AND METHODS

Materials
Cross-resistance to other drugs was determined by measuring the 50% inhibitory concentration (IC 50 ) and the resistance factor (IC 50 ratio between resistant and wild-type cells) with the colorimetric MTT dye reduction assay (48) , in which the tetrazolium salt MTT is converted to a colored formazan product by enzymes active only in living cells. The IC 50 value corresponds to the concentration of a given compound provoking 50% inhibition of cell proliferation compared with untreated cells after 3 days. The effect on pentamidine resistance of 5 M trifluoperazine (TFP), 5 M prochlorperazine (PCP), 15 M verapamil, and 1 mM buthionine sulfoximine (BSO) was studied by incubating the parasites with these compounds and different concentrations of pentamidine for 72 h, with the inhibitory effect on growth being measured as described above.
Transport studies. Parasites were harvested during the mid-logarithmic phase of growth by centrifugation at 2,100 ϫ g for 10 min at room temperature. Cells were then washed three times with phosphate-buffered saline supplemented with 1% D-glucose (PBSG) at pH 7.4 for promastigotes and pH 5.5 for amastigotes. Cells were resuspended in this buffer at densities appropriate for the procedure to be used, as indicated in the text and figure legends. Parasite suspensions (160 l, containing 2 ϫ 10 7 cells for promastigotes and 3 ϫ 10 7 cells for amastigotes) were warmed to 25°C (for promastigotes) or 32°C (for amastigotes) and mixed with 20 l of assay buffer containing labeled molecule plus or minus other test compounds at the concentrations indicated in the text. Transport was terminated by the rapid separation of parasites from the buffer components by centrifugation through a 9:1 mixture of dibutyl phthalate (specific gravity, 1.04) and mineral oil (specific gravity, 0.875 to 0.885). The sample tubes were immediately flash frozen in liquid nitrogen, and the tubes were cut to separate the pellet from the transport medium. The pellet was dissolved in 2% sodium dodecyl sulfate (250 l) and 3 ml of scintillation fluid (EcoscintA; National Diagnostics, Hessle, United Kingdom). These were left overnight to remove the effects of chemiluminescence, and then incorporated radioactivity was counted. The protein content was determined by the dye-binding method (21) and calculated as 6.1 and 2.0 g of protein/10 6 cells for L. mexicana promastigotes and amastigotes, respectively. Cell volumes were previously determined as 100 m 3 for promastigotes and 27 m 3 for amastigotes (17) . The effects of various pharmacological reagents on pentamidine accumulation in wild-type and resistant cells was investigated by resuspending cells in PBSG containing inhibitors at the concentrations indicated in the text and figure legends for 10 min at 25°C. After this treatment, 0.25 M [ 3 H]pentamidine was added to the mixture, and uptake over 10 s was measured.
In order to determine efflux of pentamidine, cells were loaded with 0.25 M [ 3 H]pentamidine for 10 min either at room temperature or on ice. After exposure to the drug, an aliquot was immediately centrifuged through oil and frozen in liquid nitrogen. Retained pentamidine was determined as described above. The remaining cells were centrifuged, washed three times with PBSG, resuspended in drug-free PBSG at 10 8 cells/ml, and incubated at 25°C or 32°C. Aliquots of cells were removed, and intracellular pentamidine was determined over a range of time points. To evaluate the effect of energy, mitochondrial membrane potential, proton motive forces, and multidrug resistance-reversing agents on pentamidine efflux, inhibitors were added simultaneously with the [ 3 H]pentamidine. Subsequently, cells were centrifuged, washed three times with PBSG containing inhibitors, and then resuspended in PBSG supplemented with the inhibitor but no pentamidine.
Analysis of kinetic data. The net uptake of pentamidine into leishmanias probably involves several components, including a plasma membrane uptake system, a plasma membrane efflux system, and a mitochondrial uptake system. Technical limitations prevented us from dissecting out each of these components, and hence we measured net uptake and expressed the values from plots of net uptake against velocity as apparent kinetic parameters. Apparent K m and V max values for pentamidine uptake were determined by measuring apparent initial uptake rates over various concentrations of pentamidine between 1 M and 1 mM. Nonlinear regression fits to the Michaelis-Menten equation with the GraFit version 4.09 for Microsoft Windows (Erithacus Software) were used to determine apparent K m and V max values. The type of inhibition and K i values for pentamidine, arginine, and other molecules were determined with the enzyme inhibition program of GraFit 4.09.
Fluorescence microscopy. Cells were incubated with 2 M 4Ј,6Ј-diamidino-2-phenylindole (DAPI) for the times marked in the text. Cells were then transferred to a microscope slide and viewed by fluorescence microscopy (excitation at 330 nm, emission at 400 nm). To permeabilize the cells, 1 M digitonin was added to the cells for 1 to 2 min before DAPI was added.
Flow cytometry. A total of 10 6 parasites were washed three times and resuspended in 1 ml of PBSG containing 250 nM rhodamine-123. The fluorescence of 10 5 cells was measured immediately after addition and 30 min later. The procedure was carried out for wild-type and resistant parasites and repeated in the presence of 10 mM pentamidine. Data were gathered with a FACSCalibur (Becton Dickinson, Oxford, United Kingdom) flow cytometer equipped with an argon-ion laser (15 mW) tuned to 488 nm. Rhodamine-123 fluorescence was collected in the photomultiplier tube designated FL1, which is equipped with a 530/30-nm band pass filter. Data analysis was carried out with CellQuest (Becton Dickinson, Oxford, United Kingdom) software.
RESULTS
Characterization of pentamidine-resistant parasites. Four cloned lines of L. mexicana promastigotes resistant to pentamidine (Pent r ) were selected in vitro by increasing drug pressure. Pent r 2.5, Pent r 5, Pent r 10, and Pent r 30 promastigotes displayed 14-, 30-, 50-, and 100-fold resistance to pentamidine, respectively (Table 1) . These resistant cells expressed crossresistance to the diamidines propamidine, stilbamidine, and berenil. Resistant promastigotes did not show any cross-resistance to sodium arsenite or to inhibitors of multidrug resistance and multidrug resistance-associated protein, which are toxic to cells in the assay conditions used ( Table 1) .
Promastigotes of the resistant line Pent r 30 were transformed in vitro to amastigotes without drug pressure because pentamidine inhibits the transformation of promastigotes to amastigotes (54) . It has previously been shown that while low-level resistance to pentamidine in L. mexicana is rapidly lost once drug selection is removed, high-level resistance is stable (54) . Here we too show that high-level pentamidine resistance was maintained for at least 6 months without pressure for promastigotes and 2 months for amastigotes (data not shown). The IC 50 of pentamidine for amastigote derivatives of Pent r 30 was 70 Ϯ 5 M, compared with 0.30 Ϯ 0.05 M for sensitive amastigotes. 50 values were determined after 72 h. Cross-resistance was not evident for the following compounds, the IC 50 values of which against the wild type are given in parentheses: AsO 2 (10 M), verapamil (50 M), vinblastine (38 M), puromycin (6.5 M), TFP (9 M), and PCP (11 M). ND, not determined.
The ability of typical P-glycoprotein inhibitors previously used to identify at least three separate efflux activities in Leishmania spp. (30) were tested for their ability to reverse pentamidine resistance. TFP (5 M), PCP (5 M), and verapamil (15 M) had no significant toxic effects on either wild-type or resistant promastigotes themselves, nor did BSO (1 mM), which inhibits glutathione biosynthesis (data not shown). However, at these concentrations, each compound provoked a reversion towards wild-type pentamidine sensitivity. The IC 50 Apparent kinetic constants for pentamidine uptake into both resistant promastigotes and amastigotes were determined with a range of substrate concentrations between 1 M and 1 mM and compared with values obtained for wild-type cells ( Table 2 ). The apparent K m value was similar for both wildtype amastigotes and promastigotes. The apparent V max value was, however, 19-fold higher in amastigotes than in promastigotes ( Effects of pharmacological inhibitors of cellular homeostasis. Pentamidine uptake was investigated in the presence and absence of different inhibitors to investigate the nature of the force driving uptake. The results indicate that classical inhibitors of mitochondrial metabolism, potassium cyanide, sodium azide, and 2,4-dinitrophenol (Table 3 ; data not shown for amastigotes), led to significant reductions in net pentamidine uptake in wild-type parasites. Ouabain, an inhibitor of the plasma membrane Na ϩ /K ϩ -ATPase (31), and monensin, an Na ϩ ionophore, did not significantly decrease pentamidine uptake in either promastigotes or amastigotes. These data in- (61) , also decreased pentamidine uptake, whereas bafilomycin A 1 , a specific vacuolar-type H ϩ -ATPase inhibitor (20) , had no effect. Verapamil, a Ca 2ϩ channel blocker and a P-glycoprotein inhibitor, inhibited pentamidine uptake. Overall, while the agents used could affect the permeability of cells independently of their effect on the proton motive force, the data are consistent with inhibition of proton motive forces associated with mitochondrial metabolism having a profound effect on the net accumulation of pentamidine into L. mexicana.
Uptake in the presence of these inhibitors was also studied in Pent r 30 promastigotes. Net pentamidine uptake in the resistant line was increased in the presence of dinitrophenol, potassium cyanide, and sodium azide compared with uptake into the resistant cells themselves (Table 3) . Valinomycin, carbonyl cyanide, N,NЈ-dicyclohexylcarbodiimide, N-ethylmaleimide, oligomycin A, and verapamil also increased pentamidine accumulation in resistant cells. These results indicate that the mitochondrial membrane potential is not involved in the accumulation of pentamidine in resistant parasites. Moreover, since most of these inhibitors also deenergize cells, they also indicate that the drug may be actively effluxed from energized cells.
Specificity of pentamidine transporter. Pentamidine was shown to be a competitive inhibitor of arginine uptake for promastigotes and amastigotes, with K i values of 12.5 Ϯ3.8 M and 16.3 Ϯ2.8 M, respectively. However, arginine had no inhibitory activity against pentamidine uptake, even at concentrations as high as 10 mM (data not shown). K m and V max values of arginine uptake were essentially identical in wild-type and pentamidine-resistant parasites (K m values were 2.3 Ϯ 0.7 M for the wild-type and 3.3 Ϯ 2.7 M for the resistant line, and V max values were 6.6 Ϯ 0.5 nmol s Ϫ1 [10 6 cells] Ϫ1 and 5.1 Ϯ 0.6 nmol s Ϫ1 [10 6 cells] Ϫ1 for the two lines, respectively). This would indicate that pentamidine does not enter cells via an arginine transporter.
The aromatic diamidines propamidine, stilbamidine, DAPI, and berenil and the phenanthridine isometamidium (Samorin) were found to be potent competitive inhibitors of pentamidine uptake, suggesting that the nature of the lateral chain is not important in recognition (Table 4) . para-Aminobenzoic acid, benzamide, and benzylamine did not affect pentamidine uptake, whereas benzamidine, 3-aminobenzamidine, and 4-aminobenzamidine all inhibited uptake, but noncompetitively.
In order to establish the specificity of the transporter, uptake of 4 M pentamidine was studied in the presence of a vast excess (1,000-fold or more) of potential competitive substrates. Polyamines (putrescine, spermidine, and spermine), amino acids (all 20 naturally occurring L-amino acids), nucleobases (adenine, guanine, cytosine, and uracil), nucleosides (adenosine, inosine, guanosine, thymidine, and cytidine), sugars (D-glucose, D-fructose, and D-galactose), and a variety of other metabolites (folic acid, biotin, choline, panthenoic acid, ethanolamine, thiamine, pterine, pyridoxal, taurine, linoleic acid, sphingosine, guanidine, urea, reduced glutathione, oxidized glutathione, ascorbic acid, and imidazole) all failed to inhibit pentamidine uptake. Two peptides rich in basic amino acids (Arg-Ser-Arg and Lys-Lys-Lys-Lys) did give modest inhibition (around 50% when used at 5 mM and 10 mM, respectively).
Inhibition was also seen with some inorganic divalent cations (74% inhibition with 5 mM Ca 2ϩ , 47% with 0.1 mM Cd 2ϩ , 45% with 0.1 mM Co 2ϩ , and 69% with 5 mM Ni 2ϩ ). Taurocholate also decreased pentamidine uptake by 50% when used at 10 mM. Taurocholate was a noncompetitive inhibitor, with a K i of 10.5 Ϯ 1.9 mM (data not shown). Pentamidine uptake was sensitive to several compounds often used as P-glycoprotein inhibitors, including TFP, PCP, and verapamil (the three drugs were competitive inhibitors, with a Efflux of pentamidine. Examining pentamidine uptake in the presence of metabolic inhibitors, including dinitrophenol, azide, and KCN, revealed significant decreases in accumulated drug in the wild-type parasites. However, these compounds increased net uptake in resistant cells, indicating that an energy-dependent efflux system for pentamidine could influence the resistance phenotype. This is in agreement with the observation that P-glycoprotein inhibitors reverse the resistance (Table 3) .
To study this more, parasites were loaded to steady state over 10 min with radiolabeled pentamidine at room temperature, and retained drug was measured for 1 h in both wild-type and resistant cells. Accumulated pentamidine reached substantially higher levels in wild-type parasites during the loading phase. An efflux of pentamidine was then observed in both wild-type and resistant cells. This represented a significant proportion (about 70%) of total accumulated drug in resistant parasites but only a small fraction (about 14%) of the total in wild-type cells (Fig. 2A) .
When cells were loaded with pentamidine on ice, both wildtype and resistant lines accumulated similar levels. When these were then transferred to room temperature and the rate of efflux was measured in both cell lines, it was shown to occur at a similar rate (Fig. 2B) , indicating that increased efflux could not explain the resistance phenotype.
Pentamidine efflux was also assayed in the presence of various metabolic inhibitors and protonophores, and this also diminished efflux (Fig. 3) . Typical inhibitors of the multidrug resistance phenotype in mammalian cells which have also been used to distinguish at least three efflux systems in Leishmania spp. (30) , including verapamil (used at 50 M), TFP, and PCP (both used at 20 M), inhibited pentamidine efflux (Fig. 3 and  4) . Treatment of the cells with 1 mM BSO for 24 h also inhibited efflux (Fig. 4) .
Pentamidine accumulation over a 6-h period was also investigated in wild-type and resistant promastigotes with or without PCP and TFP. In the presence of these inhibitors, resistant cells accumulated drug to level similar to those in the wild type by 6 h (Fig. 5) .
Intracellular compartmentalization of diamidines. Pentamidine-resistant promastigotes (Pent r 30) were treated with 1 M digitonin to permeabilize membranes without killing the 3734 BASSELIN ET AL. ANTIMICROB. AGENTS CHEMOTHER.
on April 25, 2016 by guest http://aac.asm.org/ cells in order to bypass membrane transport systems. Accumulation of pentamidine was similar in wild-type and resistant cells under these conditions (data not shown), while without digitonin the apparent rate of pentamidine uptake by resistant cells was only 10% of that of the sensitive cells (Fig. 1) . DAPI is a fluorescent analogue of pentamidine. The compound is toxic to L. mexicana promastigotes, and cells resistant to pentamidine are cross-resistant to DAPI (Table 1) . Moreover, the compound inhibits pentamidine uptake into L. mexicana ( Table 4 The ability of wild-type and resistant cells to accumulate the hydrophobic cation rhodamine-123, which is widely used as an indicator of mitochondrial membrane potential (25) , was also studied. At time zero, both wild-type and resistant cells (Pent r 30) had very similar rhodamine-123 fluorescence. However, 30 min later, a substantially greater fluorescence was evident in wild-type cells, while the fluorescence of the resistant cells was virtually unchanged since the initial time point (Fig. 6 ). This indicates that resistant cells had a reduced mitochondrial membrane potential compared with wild-type cells.
DISCUSSION
Resistance to antimicrobial agents has become a serious issue in efforts to control disease caused by pathogenic microorganisms. Understanding of the mechanisms of resistance may have value in allowing reversal of drug resistance phenotypes and also in planning use of agents which circumvent operative resistance mechanisms. Pentamidine is a drug which is widely used in the treatment of early-stage sleeping sickness caused by the parasitic protozoan T. brucei. The same drug is also used for Pneumocystis carinii pneumonia, fungal infections, and antimony-refractory leishmaniasis. Pentamidine belongs to the diamidine class of drugs, which also contains berenil (diminazene aceturate), which is used against disease caused by African trypanosomes in animals.
Recently, a series of novel diamidine drugs have been shown to be effective against P. carinii, and prodrugs that can be delivered to the body through the oral route have become available (49, 50) . Diamidines are substrates of the P2 nucleoside transporter operative in T. brucei (5, 23) . Loss of this transporter can mediate resistance to drugs which enter cells via this route (5, 22) . The situation regarding pentamidine uptake into T. brucei is complex (47) because in T. brucei, the drug also enters via at least two other transporters (29) . Leishmania parasites are related to T. brucei, although we have shown here that pentamidine does not enter Leishmania parasites via a nucleoside transporter. Moreover, Leishmania spp. do not have a functional equivalent of P2 (38, 43) . Thus, the mechanisms underpinning both sensitivity and resistance to pentamidine in Leishmania spp. must differ from those in trypanosomes.
The drug enters both promastigote and amastigote forms of the Leishmania cell via a carrier-mediated process which recognizes diamidines with high affinity. Efforts to identify a physiological substrate for the transporter were unsuccessful, although because arginine and other basic amino acids failed to inhibit uptake it appears unlikely that pentamidine enters these parasites with a basic amino acid transporter, as was previously suggested (40, 41) . Polyamines also failed to inhibit a Initial rate of 4 M pentamidine uptake was determined with different drugs added at 100 M. Results were normalized to the control value. ND, not determined; A K i could not be determined for DAPI because of solubility limits. Benzamide, benzylamine, and para-aminobenzoic acid failed to give any inhibition.
uptake, ruling out polyamine transporters as the carriers of pentamidine into the cells. A wide variety of common metabolites also failed to inhibit pentamidine uptake. Three inhibitors of P-glycoproteins (PCP, TFP and verapamil) were competitive inhibitors of uptake, but the physiological role of the leishmanial transporter that carries pentamidine into the cell remains unknown.
The affinity for pentamidine shown by its transporter in L. mexicana was unaltered in resistant parasites. However, drug accumulated to a lower level, and the apparent V max for uptake was diminished in resistant parasites. A similar situation has been noted in resistance to isometamidium in Trypansoma congolense (60) . Resistance in this case was concluded not to associate with alterations at the level of a plasma membrane transporter, but with changes in the mitochondrial membrane potential. Isometamidium rapidly enters the T. congolense mitochondrion, where it is binds tightly to kinetoplast DNA. The apparent decrease in V max in resistant cells correlated to diminished capacity to accumulate drug intracellularly (60) .
Like isometamidium, diamidines are organic cations, and they also bind to the kinetoplast. Ultrastructural changes to kinetoplast DNA and the mitochondrion are observed in parasites exposed to these drugs (26, 37, 39) . DAPI, a fluorescent analogue of pentamidine, enters cells and accumulates rapidly in the mitochondrion, binding to the kinetoplast in wild-type but not high-level pentamidine-resistant Leishmania strains. Treating cells with digitonin to render their membranes permeable revealed that the fluorescent diamidine bound equally well to wild-type and resistant kinetoplasts, indicating that it is access to the kinetoplast rather than the ability to bind to the DNA that differentiates wild-type and resistant cells. Previous studies have pointed to a diminution of mitochondrial membrane potential in pentamidine-resistant Leishmania spp. (11) , and accumulation of rhodamine-123 also indicates that mitochondrial membrane potential is diminished in the drug-resistant lines analyzed in this study.
The data presented here are consistent with a model similar to that proposed for isometamidium resistance in T. congolense. Pentamidine appears to enter both resistant and wildtype cells via the same plasma membrane carrier, which is unaltered in the resistant lines. However, in wild-type but not resistant parasites, the drug is rapidly accumulated in the mitochondrion, with uptake being driven by the greater mitochondrial membrane potential of wild-type cells. In contrast, in resistant parasites, the drug does not accumulate rapidly in the mitochondrion but remains free in the cytosol. Efflux pumps appear to be operative in removing cytosolic and membraneassociated pentamidine from the cell, and it is likely that the pumps can remove the majority of the pentamidine from the nonmitochondrial compartment of both cell types.
This pentamidine efflux system is operative in both cell types, but in the wild-type cells, most of the pentamidine becomes bound to the kinetoplast, within the mitochondrion, and so is not available for efflux, thus remaining in the cell. This is not the case in the resistant parasites. A balance involving rate of uptake into the cell, efflux from the cell at the plasma membrane, and accumulation in the mitochondrion would then underlie the events reported here. Agents which inhibit efflux may lead to reversal of resistance by allowing pentamidine to accumulate in the cytosol to levels which then drive accumulation in the mitochondrion. In S. cerevisiae, a gene, PNT1, whose overexpression mediates pentamidine resistance, encodes a product that is targeted to the mitochondrion and is involved in the biogenesis of that organelle as a protein translocator (36) . The mitochondrion appears to be the target of pentamidine action in S. cerevisiae, and based on the data presented here, it would appear that the mitochondrion also plays a crucial role in the mode of action for pentamidine in Leishmania parasites.
